[1] [2] Patients with severe gastrointestinal disease, including gastroparesis, should use semaglutide with caution
PubMed: (peer-reviewed) U.S
Zepbound's strong 3-year maintenance data (while on treatment) is promising
Another advantage is that nausea, which is a common side effect of GLP-1 drugs, tends to be less with tirzepatide because GIP appears to have an anti-nausea effect. Think of it as turning up the volume on a signal your body already uses Your body already knows how to use GLP-1 and GIP
It slows bacterial growth rather than eliminating it entirely, and it does nothing to prevent the introduction of endotoxins or other non-living contaminants
The trade-off is borne entirely by the patient: higher rates of severe nausea, increased early dropout, and greater likelihood of metabolic adaptation (the body down-regulating GLP-1 receptors in response to abrupt dose increases)